Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Stoke Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Stoke Therapeutics's regulatory disclosures and financial reporting.
Stoke Therapeutics director Arthur A. Levin received a grant of stock options covering 17,786 shares of common stock. The options have an exercise price of $29.46 per share and expire on June 2, 2036. According to the grant terms, the award vests in full on the earlier of June 3, 2027 or the company’s next annual stockholder meeting, contingent on Levin’s continued service.
Stoke Therapeutics director Adrian R. Krainer received a grant of 17,786 stock options to buy common shares at $29.46 each. These Director Stock Options were awarded for compensation, not purchased on the open market, and are held as a direct beneficial interest.
The options vest in full on the earlier of June 3, 2027 or the date of the company’s next annual stockholder meeting, as long as Krainer continues serving the company through that date. Following this grant, he holds 17,786 options covering the same number of common shares, which may be exercised before their expiration on June 2, 2036.
Stoke Therapeutics, Inc. reported that director Edward M. Kaye, MD received a grant of options to acquire 17,786 shares of Common Stock. The options have an exercise price of $29.46 per share and expire on June 2, 2036.
According to the terms, the option vests in full on the earlier of June 3, 2027 or the date of the company’s next annual stockholder meeting, subject to his continued service with the company through that vesting date. This is a compensation-related award rather than an open-market stock purchase.
Stoke Therapeutics director Seth Loring Harrison received a grant of 17,786 stock options. These Director Stock Options give him the right to buy 17,786 shares of common stock at an exercise price of $29.46 per share and are held directly.
The options vest in full on the earlier of June 3, 2027 or the date of Stoke Therapeutics’ next annual stockholder meeting, as long as he continues serving the company through that vesting date. The options expire on June 2, 2036, and this grant represents his full reported option position in this filing. This is a compensation award, not an open‑market stock purchase or sale.
Stoke Therapeutics director Jennifer Burstein received a grant of stock options covering 17,786 shares of common stock. These options have an exercise price of $29.46 per share and expire on June 2, 2036. The filing shows she holds 17,786 derivative securities following this grant. According to the vesting terms, the option will vest in full on the earlier of June 3, 2027 or the date of Stoke Therapeutics’ next annual stockholder meeting, provided she continues serving the company through that vesting date.
Stoke Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. Stockholders elected directors G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D., and Julie Anne Smith, each receiving tens of millions of shares voted in favor versus relatively small withheld votes, plus broker non-votes.
Stockholders also approved one proposal with 55,121,163 shares for, 2,036 against, and 51,714 abstaining, and another with 36,436,275 shares for, 13,565,293 against, 29,415 abstaining, and 5,143,930 broker non-votes. The filing confirms that these meeting outcomes are now formally recorded.
Stoke Therapeutics, Inc. Chief Medical Officer Barry Ticho reported an open-market sale of 1,795 shares of common stock at $30.58 per share. After the transaction, he directly holds 34,826 shares. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025, indicating it was scheduled in advance.
Stoke Therapeutics reports a Schedule 13G/A showing beneficial ownership of 4,763,673 shares (8.1% of the class). The filing states this percentage is calculated using 59,150,790 shares outstanding as of February 28, 2026. The holdings are reported by Lynx1 Capital Management LP and Weston Nichols and consist of 4,121,244 shares previously reported for the quarter ended March 31, 2026 plus an additional 642,429 shares.
Stoke Therapeutics Schedule 13G/A (Amend. No. 3) reports that Lynx1 Capital Management and Weston Nichols beneficially own 4,121,244 shares of Stoke Therapeutics common stock, representing 7.0% of the class. The filing cites 59,150,790 shares outstanding as of February 28, 2026 from the company’s Form 10-K.
The disclosure attributes the shares to the Lynx1 Fund and a managed account, shows shared voting and dispositive power over the reported shares, and states that the Lynx1 Fund has the right to receive dividends or sale proceeds. Signatures are by Weston Nichols on behalf of Lynx1 and individually.
Stoke Therapeutics, Inc. ownership update: an amended Schedule 13G/A shows Redmile Group, LLC and related entities report beneficial ownership of common stock as of March 31, 2026. The filing states Redmile Group, LLC and Jeremy C. Green each have 4,164,120 shares (representing 6.7% of the class) and Redmile Biopharma Investments III, L.P. holds 3,505,612 shares (5.6%), based on 62,240,347 shares outstanding as of March 31, 2026. The filing attributes shared voting and dispositive power to Redmile for these holdings and includes standard disclaimers of beneficial ownership except for pecuniary interest.